Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice

By Ruddy Kathryn   Desantis Stephen   Gelman Rebecca   Wu Alan   Punglia Rinaa   Mayer Erica   Tolaney Sara   Winer Eric   Partridge Ann   Burstein Harold  

Breast Cancer Research and Treatment, Vol. 141, Iss. 3, 2013-10 ,pp. : 421-427

Springer Publishing Company

Access to resources Recommend Favorite

Concurrent use of tamoxifen with CYP2D6 inhibitors and the risk of breast cancer recurrence

By Azoulay Laurent  

Breast Cancer Research and Treatment, Vol. 126, Iss. 3, 2011-04 ,pp. : 695-703

Springer Publishing Company

Access to resources Recommend Favorite

Pharmacogenetics of Aromatase Inhibitors in Endocrine Responsive Breast Cancer: Lessons Learnt from Tamoxifen and CYP2D6 Genotyping

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 17, Iss. 13, 2018-01 ,pp. : 1805-1813

Bentham Science Publishers

Access to resources Recommend Favorite

Behaviour of metastasis in relation to vascular index in patients with node-positive breast cancer treated with adjuvant tamoxifen

By Gasparini Giampietro   Fanelli Massimo   Boracchi Patrizia   Morabito Alessandro   Locopo Nathalia   Biganzoli Elia  

Clinical and Experimental Metastasis, Vol. 18, Iss. 1, 2000-01 ,pp. : 15-20

Springer Publishing Company

Access to resources Recommend Favorite

Long-term follow-up of the randomized Stockholm trial on adjuvant tamoxifen among postmenopausal patients with early stage breast cancer

By Rutqvist Lars   Johansson Hemming   Group on behalf of the Stockholm Breast Cancer Study  

Acta Oncologica, Vol. 46, Iss. 2, 2007-01 ,pp. : 133-145

Informa Healthcare

Access to resources Recommend Favorite